Bristol Myers Squibb

BMS will expand its NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems to train proprietary foundation models, building on nearly three years of NVIDIA collaboration.

Partners: NVIDIA

BMS says agents automate target identification as well as validation, saving weeks of manual work for its scientists.

Under its Predict First approach, BMS says AI-generated predictions inform the design of every small-molecule program and most large-molecule programs before bench work.

BMS announced a strategic agreement to deploy Anthropic's Claude, including Claude Code and agentic workflows, across research, development, manufacturing, commercial and corporate functions for more than 30,000 employees.

Partners: Anthropic

BMS describes private in-house ChatGPT and GenAI tools that employees use to upload documents, summarize information, plan projects and find company information.

insitro says BMS nominated two more ALS targets identified via insitro's AI-driven Virtual Human platform, expanding their collaboration.

Partners: insitro

VantAI announced a collaboration with BMS using its generative AI and geometric deep learning to identify molecular glues, with up to $674 million in milestones.

Partners: VantAI

BMS describes MyGrowth, an AI-enabled internal talent marketplace that matches employees with roles, projects and learning recommendations.

BMS says it uses reinforcement AI to deliver personalized content to physicians through digital channels.